Aim: This study aims to investigate any modification of serological FSCN1 in prostate cancer patients compared with patients without neoplasia. Material & methods: Clinical data and blood specimens from patients with and without prostate cancer were obtained. A quantitative sandwich ELISA method was used to determine serological values of FSCN1. Results: Although serum values of FSCN1 were dissimilar in the two cohorts of patients (6.90 vs 7.33 ng/ml), the difference was not statistically significant (p = 0.20). Serum values of FSCN1 stratified for Gleason score groups were not significantly distinguishable (p = 0.65). A negative correlation (rho = -0.331; p = 0.009) was reported between FSCN1 and age. Conclusion: Further studies are required to evaluate a possible diagnostic role of FSCN1 in prostate cancer.
Fascin-1 and its role as a serological marker in prostate cancer: A prospective case-control study / O.S. Tataru, O. Martha, F. Crocetto, B. Barone, S. Voidazan, A. Borda, A. Sin, A. Hutanu, A. Loghin, I. Sin, D. Porav-Hodade, C.B. Chibelean, L. Vartolomei, G. Lucarelli, M. Ferro, V.G. Osan, C. Buonerba, M.D. Vartolomei. - In: FUTURE SCIENCE OA. - ISSN 2056-5623. - 7:9(2021), pp. FSO745.1-FSO745.11. [10.2144/fsoa-2021-0051]
Fascin-1 and its role as a serological marker in prostate cancer: A prospective case-control study
G. Lucarelli;M. Ferro;
2021
Abstract
Aim: This study aims to investigate any modification of serological FSCN1 in prostate cancer patients compared with patients without neoplasia. Material & methods: Clinical data and blood specimens from patients with and without prostate cancer were obtained. A quantitative sandwich ELISA method was used to determine serological values of FSCN1. Results: Although serum values of FSCN1 were dissimilar in the two cohorts of patients (6.90 vs 7.33 ng/ml), the difference was not statistically significant (p = 0.20). Serum values of FSCN1 stratified for Gleason score groups were not significantly distinguishable (p = 0.65). A negative correlation (rho = -0.331; p = 0.009) was reported between FSCN1 and age. Conclusion: Further studies are required to evaluate a possible diagnostic role of FSCN1 in prostate cancer.
| File | Dimensione | Formato | |
|---|---|---|---|
|
fsoa-07-745.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
712.11 kB
Formato
Adobe PDF
|
712.11 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
